Can the cosentyx dose be adjusted for adult arthritis?

Can Cosentyx dosing be adjusted for adult arthritis patients?

Yes. Cosentyx dosing can be adjusted for certain patients with adult arthritis based on individual response and clinical judgment. The recommended dose for psoriatic arthritis and ankylosing spondylitis is 150 mg injected subcutaneously once a month, after an initial series of five weekly doses. After reaching maintenance, some physicians adjust by either increasing the monthly dose to 300 mg or keeping it at 150 mg depending on how well the patient responds.

Why do some patients need a higher dose?

Some patients show inadequate response at 150 mg. The manufacturer recommends the 300 mg monthly maintenance dose for those who did not respond adequately to TNF blockers or who are heavy smokers. Heavy smokers show reduced clinical response to Cosentyx, so the doppelganger dose recommendation applies to smokers as well. The 300 mg monthly maintenance dose is achieved by two 150 mg injections at each visit.

What happens if the monthly maintenance dose is increased to 300 mg?

Switching to 300 mg allows more patients to reach ACR20 and ACR50 responses than staying at 150 mg. The approved label allows physician discretion in choosing 150 mg or 300 mg after the initial five weekly 150 mg doses. The approved label also allows physician discretion in choosing 150 mg or 300 mg for non-radiographic axial spondyloarthritis.

What happens if the monthly maintenance dose is reduced to 150 mg?

Keeping the 150 mg monthly dose shows sufficient response in many patients. Many patients achieve ACR20 and ACR25 responses at 150 mg, already high enough for med<|eos|>